CLINICAL EVIDENCE
Explore the science behind PARIS®.
Cure First’s work in functional precision oncology is grounded in research exploring how living tumor cells can provide information beyond molecular profiling alone.
Explore peer-reviewed publications, clinical studies, case reports, posters and abstracts related to PARIS, functional drug testing and the science that led to the development of the platform.
SCIENTIFIC CREDIBILITY
Built on research. Available for clinical use.
Cure First’s work in functional precision oncology is supported by published research and the clinical availability of the PARIS Test.
CLIA Certified Laboratory
50 States
Peer Reviewed Science
FEATURED EVIDENCE
Science advancing functional precision oncology.
Explore selected research highlighting the scientific foundation, clinical application and ongoing development of functional precision oncology and the PARIS platform.
Ex vivo pharmacotyping of tumor-derived organoids identifies personalized therapeutic options for patients with biliary tract cancerReview patient eligibility, sample requirements and ordering information for the PARIS Test, or connect with the Cure First team to discuss questions about a patient.
Richardson AB*, Chatterjee P*, et al. | Cancer Research Communications | 2026
This research applies ex vivo drug testing to patient-derived tumor organoids to identify personalized therapeutic options in biliary tract cancer. It directly supports the functional precision oncology approach underlying PARIS by testing treatment response in living tumor models.
VIEW ORIGINAL SOURCE >
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing.
Gray HJ, Chatterjee P, Rosati R, et al. | NPJ Precision Oncology | 2023
This report describes a clinical response to a therapy selected with the guidance of organoid drug testing in low-grade ovarian cancer. It provides a direct example of functional precision oncology informing an individualized treatment decision.
VIEW ORIGINAL SOURCE >
The promise of functional precision medicine
Kemp CJ, Grandori C. | Trends in Cancer | 2019
This article describes the rationale and potential of functional precision medicine as a complement to genomics-based cancer care. It provides foundational context for the approach embodied by PARIS: directly testing therapeutic response in patient-derived cancer models.
VIEW PUBLICATION >
Personalized in vitro and in vivo cancer models to guide precision medicine
Pauli C, et al. | Cancer Discovery | 2017
This study evaluates personalized cancer models as tools to guide precision medicine. Its use of patient-specific models supports the principle behind functional precision oncology: testing therapies in biologically relevant models derived from an individual patient's cancer.
VIEW PUBLICATION >
Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma
Shigeta S, et al. | Molecular Cancer Therapeutics | 2021
This study identifies a combination therapeutic strategy for ovarian clear cell carcinoma through functional investigation of drug targets and pathways. It supports the broader functional genomics framework used to uncover actionable treatment vulnerabilities.
VIEW PUBLICATION >
Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer
Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R, Moser RD, et al. | Clinical Cancer Research | 2018
This study demonstrates that functional precision medicine can identify druggable targets and therapeutic options in head and neck cancer. It supports the use of functional testing to uncover actionable treatment opportunities that may not be evident from genomics alone.
VIEW PUBLICATION >
Functional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima M, et al. | Proceedings of the National Academy of Sciences of the United States of America | 2012
This study uses functional genomics to identify therapeutic targets in MYC-driven cancer. It provides foundational evidence that experimentally testing cancer dependencies can reveal actionable vulnerabilities for treatment development.
VIEW PUBLICATION >
Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy
Narasimhan V, Wright JA, Churchill M, et al. | Clinical Cancer Research | 2020
This study uses drug screening of patient-derived organoids from colorectal peritoneal metastases to help direct personalized therapy. It closely aligns with PARIS by evaluating treatment response directly in living patient-derived tumor models.
VIEW PUBLICATION >
Patient-derived organoids to model rare prostate cancer phenotypes
Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. | Nature Communications | 2018
This research uses patient-derived organoids to model rare prostate cancer phenotypes. It supports the scientific foundation for using living tumor models to study individual cancers and evaluate biologically relevant therapeutic vulnerabilities.
VIEW PUBLICATION >
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Lui GYL, et al. | EbioMedicine | 2020
This research identifies synergistic drug combinations in ovarian cancer through functional testing of therapeutic vulnerabilities. It demonstrates how functional approaches can reveal potentially actionable combinations beyond single-agent genomic predictions.
VIEW PUBLICATION >
Pan-cancer alterations of the MYC oncogene and its proximal network across the Cancer Genome Atlas
Schaub FX, et al. | Cell Systems | 2018
This pan-cancer study characterizes alterations involving MYC and its proximal network across tumor types. It contributes to the functional genomics foundation for identifying cancer dependencies and therapeutic targets.
VIEW PUBLICATION >
CLINICAL STUDIES & CASE REPORTS
From research to clinical application.
Clinical studies and case reports provide insight into the application of functional precision oncology and PARIS testing in individual patient and clinical settings.
Case report: Ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma
Al-Aloosi M, Prechtl AM, Chatterjee P, et al. | Frontiers in Oncology | 2024
This case report demonstrates how ex vivo tumor organoid drug testing can identify therapeutic options for a patient with advanced ovarian cancer. It illustrates the clinical relevance of functional testing using living patient-derived tumor cells.
VIEW PUBLICATION >
Complete remission of widely metastatic human epidermal growth factor receptor 2-amplified pancreatic adenocarcinoma after precision immune and targeted therapy with description of sequencing and organoid correlates
King DA, Smith AR, Pineda G, et al. | JCO Precision Oncology | 2023
This report describes complete remission in metastatic pancreatic cancer following precision immune and targeted therapy, with both sequencing and organoid correlates. It highlights how functional organoid data can complement molecular information in precision oncology.
VIEW PUBLICATION >
PARIS IN CLINICAL PRACTICE
Have a patient in mind?
PARIS Testing & Ordering
Review patient eligibility, sample requirements and ordering information for the PARIS Test, or connect with the Cure First team to discuss questions about a patient.
PARIS TESTING & ORDERING >
Questions about a patient?
Connect with the Cure First team to discuss questions about PARIS for a patient.